Moreover, recent studies demonstrated that, in addition to elevated amyloidosis, the regional extent of tau burden appears to accelerate clinical progression in CN [38, 41], suggesting that the coexistence of amyloidosis and regional tau deposition may help in identifying the individuals at higher risk of short-term cognitive decline. This evidence concerns the gene MAPT and Mental deterioration.